Key regions: Europe, India, Canada, Italy, South Korea
Bronchodilator drugs are gaining popularity in Bangladesh due to the rising prevalence of respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).
Customer preferences: In Bangladesh, customers prefer bronchodilator drugs that provide quick relief from respiratory symptoms like shortness of breath and wheezing. They also prefer drugs that have fewer side effects and are affordable.
Trends in the market: The bronchodilator drugs market in Bangladesh is expected to grow steadily in the coming years due to the increasing prevalence of respiratory diseases. The market is also being driven by the introduction of new and innovative drugs that provide better symptom relief and have fewer side effects. Additionally, the growing awareness about respiratory diseases and the importance of early diagnosis and treatment is also contributing to the growth of the market.
Local special circumstances: Bangladesh has a high prevalence of respiratory diseases due to factors like air pollution, smoking, and poor indoor air quality. The country also has a large population of low-income individuals who may not have access to healthcare facilities or may not be able to afford expensive medications. As a result, there is a high demand for affordable bronchodilator drugs in the country.
Underlying macroeconomic factors: The healthcare sector in Bangladesh is rapidly growing, with the government investing in improving healthcare infrastructure and increasing access to healthcare services. The country also has a large population of young adults who are more susceptible to respiratory diseases. Additionally, the rising disposable income and changing lifestyles of the middle class is leading to an increase in healthcare spending and a growing demand for better healthcare services. These factors are expected to drive the growth of the bronchodilator drugs market in Bangladesh in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
